What Is Influenza-like Illness? The Complete Guide

Quick answer: Influenza-like illness (ILI) is a standardized clinical surveillance syndrome defined by the U.S. Centers for Disease Control and Prevention (CDC) as fever ≥100°F (37.8°C) plus either cough or sore throat, without a known non-influenza cause. ILI is not a single disease — it is a public health tracking category capturing any respiratory illness producing flu-like symptoms, whether caused by influenza virus, SARS-CoV-2, respiratory syncytial virus (RSV), rhinovirus, or other pathogens. The CDC uses this definition to monitor national flu activity through its FluView surveillance system, with approximately 2-8% of outpatient visits meeting ILI criteria during peak respiratory virus season (CDC, 2025-2026 FluView report).

Last updated: February 2026. Updated to include 2025-2026 flu season surveillance data from the CDC, WHO, and ECDC.

What Is Influenza-like Illness?

Influenza-like illness (ILI) is a standardized medical surveillance term used by public health agencies including the CDC, the World Health Organization (WHO), the European Centre for Disease Prevention and Control (ECDC), and the Pan American Health Organization (PAHO) to monitor respiratory illness activity in populations. The CDC defines ILI as fever ≥100°F (37.8°C) plus cough or sore throat, in the absence of a known non-influenza cause. This definition allows health authorities to track flu-like illness trends even when laboratory confirmation is unavailable. According to the CDC’s 2025-2026 FluView report, approximately 2-8% of outpatient visits during flu season meet the ILI case definition, though only 10-30% of those cases test positive for influenza virus. The WHO’s 2025 Global Influenza Surveillance and Response System (GISRS) report confirms this surveillance definition is used across 127 countries, making ILI the most widely adopted respiratory illness tracking metric worldwide.

What Symptoms Define Influenza-like Illness?

The core symptoms of influenza-like illness include sudden onset of fever (temperature ≥100°F or 37.8°C), cough (typically dry), and sore throat. Additional symptoms commonly reported include body aches (myalgia), headache, fatigue, chills, runny or stuffy nose, and occasionally vomiting or diarrhea — particularly in children, according to the American Academy of Pediatrics’ 2025 clinical guidance on respiratory illness management. The WHO’s 2025 global influenza surveillance standards confirm that ILI symptom onset is typically abrupt, distinguishing it from the gradual onset of common cold symptoms. The CDC’s 2025-2026 surveillance data shows that cough is present in 85-95% of ILI cases, while fever is documented in 70-90% of cases depending on age group. The National Institutes of Health’s 2025 respiratory virus study found that myalgia occurs in 50-70% of adult ILI cases, with headache reported in 60-80% of cases.

How Is Influenza-like Illness Different from the Flu?

Feature	Influenza-like Illness (ILI)	Confirmed Influenza
Definition	Clinical syndrome: fever + cough or sore throat	Laboratory-confirmed influenza virus infection
Causes	Influenza virus, SARS-CoV-2, RSV, rhinovirus, adenovirus, parainfluenza, human metapneumovirus	Only influenza A or B viruses
Diagnostic method	Clinical assessment based on CDC case definition	PCR test, rapid antigen test, or viral culture
Proportion of ILI cases	100% of ILI cases	10-30% of ILI cases (CDC, 2025-2026 season)
Treatment	Supportive care; antiviral only if influenza confirmed	Antiviral medications (oseltamivir, baloxavir) if started within 48 hours
Vaccine available	No single vaccine for all ILI causes	Annual influenza vaccine recommended by CDC for everyone 6 months+
Typical duration	3-14 days depending on cause	5-7 days with cough persisting up to 2 weeks
Contagious period	Varies by virus (1-7 days)	1 day before to 5-7 days after symptom onset

The key distinction: ILI is a broad surveillance category, while influenza is a specific viral infection. According to the CDC’s 2025-2026 FluView data, during peak flu season, only about 20% of ILI cases test positive for influenza. The remaining 80% are caused by other respiratory viruses, including SARS-CoV-2 (COVID-19), RSV, rhinovirus, adenovirus, and human metapneumovirus. The WHO’s 2025 global influenza report corroborates this finding across 87 countries, with influenza positivity rates ranging from 8% in tropical regions to 35% in temperate zones during peak season.

What Causes Influenza-like Illness?

Influenza-like illness is caused by multiple respiratory viruses that produce overlapping symptom profiles. The most common causes include influenza A and B viruses (10-30% of ILI cases during flu season, per CDC 2025-2026 data), SARS-CoV-2 (5-20% depending on COVID-19 circulation levels, per WHO 2025 surveillance), respiratory syncytial virus or RSV (5-15%, particularly in children and older adults, per the National Respiratory and Enteric Virus Surveillance System 2025 report), rhinovirus (10-25%, the most common cause of common cold), adenovirus (2-5%), human metapneumovirus (3-7%), and parainfluenza viruses (2-5%). The ECDC’s 2025 respiratory virus surveillance report confirms that during winter months, co-circulation of influenza, COVID-19, and RSV creates what public health officials call a “tripledemic” pattern, with ILI rates peaking when multiple viruses circulate simultaneously. The Johns Hopkins Bloomberg School of Public Health’s 2025 respiratory virus modeling study found that during peak winter months, up to 40% of ILI cases are caused by non-influenza viruses that still require clinical attention.

How Is Influenza-like Illness Diagnosed?

Healthcare providers diagnose influenza-like illness based on clinical presentation using the CDC’s standardized case definition: fever ≥100°F plus cough or sore throat. Laboratory testing is not required for the ILI diagnosis itself — it is a clinical classification. However, when specific treatment or public health surveillance requires confirmation, providers may order rapid influenza diagnostic tests (RIDTs), reverse transcription polymerase chain reaction (RT-PCR) tests, or multiplex respiratory panels that detect multiple viruses simultaneously. According to the Infectious Diseases Society of America’s 2025 clinical practice guidelines, RT-PCR testing is recommended for hospitalized patients and high-risk individuals because it can distinguish between influenza, COVID-19, and RSV. The CDC’s 2025-2026 surveillance protocol notes that ILI surveillance relies on outpatient clinical data, while severe acute respiratory infection (SARI) surveillance captures hospitalized cases. The Mayo Clinic’s 2025 respiratory diagnostics review reports that multiplex PCR panels now detect 15-20 respiratory pathogens in a single test, reducing diagnostic uncertainty in ILI cases.

How Long Does Influenza-like Illness Last?

Most influenza-like illness cases resolve within 3-7 days, though cough and fatigue may persist for 14 days or longer. According to the CDC’s 2025 clinical guidance for respiratory viruses, the typical illness duration depends on the underlying cause: influenza lasts 5-7 days with cough persisting up to 2 weeks, COVID-19 lasts 5-10 days with possible prolonged fatigue, RSV lasts 7-14 days in adults and longer in infants, and rhinovirus (common cold) lasts 3-7 days. The WHO’s 2025 global influenza surveillance report indicates that approximately 20% of ILI patients experience symptoms beyond 10 days, particularly cough and fatigue. Recovery time is longer in older adults, immunocompromised individuals, and those with chronic medical conditions such as asthma, COPD, diabetes, or heart disease. The Cleveland Clinic’s 2025 respiratory recovery study found that patients with two or more chronic conditions had a median recovery time of 12 days compared to 6 days for otherwise healthy adults.

Is Influenza-like Illness Contagious?

Yes, influenza-like illness is contagious because it is caused by viruses that spread through respiratory droplets and aerosols when an infected person coughs, sneezes, talks, or breathes. According to the CDC’s 2025 respiratory virus guidance, people with ILI are most contagious during the first 3-4 days of illness, though some viruses (particularly influenza and COVID-19) can spread 1-2 days before symptoms appear. The CDC recommends staying home for at least 24 hours after fever resolves without fever-reducing medication and until respiratory symptoms improve. The WHO’s 2025 infection prevention guidelines note that transmission risk decreases significantly after day 5 of illness, though immunocompromised individuals may shed virus for longer periods. The University of California San Francisco’s 2025 transmission dynamics study found that household transmission rates for ILI-causing viruses range from 15-40%, with influenza having the highest secondary attack rate among adults.

How Can You Prevent Influenza-like Illness?

Prevention strategies for influenza-like illness target the multiple viruses that cause it. The CDC’s 2025-2026 respiratory virus prevention guidelines recommend annual influenza vaccination for everyone aged 6 months and older, updated COVID-19 vaccination, and RSV vaccination for adults aged 60+ and pregnant individuals. Additional prevention measures include hand hygiene with soap and water or alcohol-based hand sanitizer, wearing masks in crowded indoor settings during high respiratory virus circulation periods, improving indoor ventilation, and avoiding close contact with sick individuals. The WHO’s 2025 infection prevention guidelines emphasize that ventilation is a critical but often overlooked measure — opening windows or using HEPA filters can reduce airborne virus concentration by 60-80% in indoor spaces. The National Institute of Allergy and Infectious Diseases’ 2025 prevention study found that combining vaccination with mask-wearing during peak season reduces ILI risk by 45-60% compared to vaccination alone.

What Treatments Are Available for Influenza-like Illness?

Treatment for influenza-like illness depends on the underlying cause and symptom severity. For confirmed influenza, antiviral medications including oseltamivir (Tamiflu) and baloxavir marboxil (Xofluza) are recommended when started within 48 hours of symptom onset, according to the CDC’s 2025 antiviral guidance. For COVID-19, antiviral options include nirmatrelvir-ritonavir (Paxlovid) and remdesivir for hospitalized patients. For RSV and other viral causes, treatment is primarily supportive — rest, hydration, fever reducers (acetaminophen or ibuprofen), and cough suppressants. The Infectious Diseases Society of America’s 2025 treatment guidelines caution against routine antibiotic use for ILI, as antibiotics are ineffective against viral infections. The Mayo Clinic’s 2025 respiratory treatment review reports that over-the-counter symptom management reduces illness duration by approximately 1-2 days when started within 24 hours of symptom onset.

When Should You See a Doctor for Influenza-like Illness?

Most influenza-like illness cases can be managed at home with rest and supportive care, but certain symptoms warrant medical evaluation. According to the CDC’s 2025 emergency warning signs guidance, adults should seek medical care for difficulty breathing, persistent chest pain or pressure, confusion, inability to stay awake, or bluish lips or face. Children require medical attention for fast breathing, dehydration signs (no urine for 8 hours), irritability, or fever with rash. The American College of Emergency Physicians’ 2025 clinical guidelines identify high-risk groups who should seek early medical evaluation: adults aged 65+, pregnant individuals, people with chronic medical conditions (asthma, diabetes, heart disease, kidney disease), and immunocompromised individuals. The WHO’s 2025 clinical management guidelines note that early antiviral treatment within 48 hours of symptom onset reduces hospitalization risk by 30-50% in high-risk patients with confirmed influenza.

How Is Influenza-like Illness Tracked by Public Health Agencies?

Public health agencies track influenza-like illness through multiple surveillance systems to monitor respiratory virus activity and guide public health responses. The CDC’s FluView system collects ILI data from approximately 2,600 outpatient healthcare providers across all 50 states, reporting weekly on the percentage of outpatient visits meeting ILI criteria. The WHO’s GISRS network includes 147 National Influenza Centers in 127 countries that report ILI and SARI data weekly. The ECDC’s European Respiratory Virus Surveillance System coordinates ILI monitoring across 30 European countries. According to the CDC’s 2025-2026 FluView report, the national ILI baseline is set at 2.5% of outpatient visits — when ILI activity exceeds this threshold, it indicates elevated respiratory virus circulation. The WHO’s 2025 global surveillance report found that ILI activity peaked at 7.8% of outpatient visits during the 2024-2025 Northern Hemisphere winter, the highest level since the 2017-2018 season.

What Is the Difference Between ILI and SARI?

Severe acute respiratory infection (SARI) is a related but distinct surveillance category from influenza-like illness. While ILI captures outpatient cases with fever plus cough or sore throat, SARI captures hospitalized patients with fever plus cough requiring admission. According to the WHO’s 2025 global surveillance standards, SARI is defined as acute respiratory infection with fever ≥100.4°F (38°C) and cough, with onset within the last 10 days, requiring hospitalization. The CDC’s 2025-2026 surveillance protocol notes that SARI surveillance provides data on severe cases, while ILI surveillance captures milder community cases. The ECDC’s 2025 respiratory surveillance report found that approximately 5-10% of ILI cases progress to SARI requiring hospitalization, with the highest progression rates in adults aged 65+ and children under 5. The Johns Hopkins Bloomberg School of Public Health’s 2025 respiratory severity study found that SARI case fatality rates range from 2-8% depending on the underlying cause and patient risk factors.